Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin plus intensive chemotherapy for newly diagnosed core binding factor acute myeloid leukemia
ACTRN12612000847819Phase 2Withdrawn
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in acute myeloid leukemia (AML), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Failure-free survival and Leukemia-free survival. Planned start Mar 2013; status: withdrawn.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12612000847819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000847819.